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Trachoma remains the most important cause in the world of blindness and loss of 
sight. It is a  disease that is particularly important in many of the underdeveloped 
countries where  the  incidence is high  and  where  the  loss of sight in  young adults 
causes a  serious economic loss, and  may play a  role in  retarding industrialization. 
Although trachoma can be cured by several antibiotics and sulfa drugs, attempts to 
eradicate the  disease through  mass antibiotic campaigns have  shown  success only 
in the more developed countries. Studies of antibiotic treatment are continuing partic- 
ularly  in  association with  the  World Health  Organization's campaigns  and  more 
effective programs may be developed (1).  Research  on  trachoma has  been  greatly 
retarded by the unavailability until recently of the etiologic agent for study in the 
laboratory. Although trachoma virus has been recognized for many years to be re- 
lated  to  the psittacosis-lymphogranuloma venereum  (P-LV)  group  of agents based 
on the morphology of inclusion bodies seen in conjunctival cell smears, efforts to grow 
the virus in series and in quantity had been unsuccessful. Although it is likely that 
the virus was isolated a number of times in the past in embryonated hen egg yolk sac, 
it had never been maintained in culture until Tang and his colleagues in 1957 (2) suc- 
ceeded in growing viral agents which were sent to England and confirmed by Collier 
and Sowa (3). The Chinese workers showed that these viral agents as isolated from 
trachoma patients' eyes were highly susceptible to penicillin but resistant to strepto- 
mycin.  By  using  streptomycin to  control  bacterial contamination  in  eggs,  similar 
agents have  been isolated from  trachomatous patients in a  number of laboratories 
throughout  the  world.  These  agents which  are  related  by group  antigen  to  P-LV 
viruses are now generally accepted as the cause of trachoma. This acceptance is based 
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on isolation of these viruses from trachomatous disease,  accompanied by development 
of antibody against the agents and by the reproduction of trachoma following experi- 
mental infection of humans. 
The six infections reported in this paper represent an experiment which has been 
carried out in order to establish  definitely the etiologic role of these  viruses by re- 
production of trachoma. In these six infections with a Taiwan strain and in two with 
an African strain carried out by Collier  and coworkers (4,  5),  the disease  has been 
allowed  to continue long enough to demonstrate  the chronic cicatricial  changes of 
trachoma.  In addition,  a  single  human infection with  a  local strain  followed for a 
month with demonstration of pannus formation, has been carried out in Israel (6) 
and South Africa (7). These human experiments greatly increase the probability that 
these  large  viral  agents  are  the  cause  of trachoma  throughout  the  world.  A  pre- 
liminary report of the first 4 months' course of the Taiwan experimental  infections 
has been published (8). 
With availability of the etiologic agent of trachoma for study in the labora- 
tory, there has been considerable interest in the possibility of developing a vac- 
cine for prevention of trachoma. However, a  number of serious problems need 
to be answered before the feasibility of a vaccine in the prevention of trachoma 
can  be  judged.  The  P-LV viruses  are  considered  poor  antigens.  Frequently, 
natural  infection  with  these  agents  does  not  evoke  an  adequate  antibody 
response to eradicate completely the organisms. Chronic foci and relapsing dis- 
ease  are  a  frequent  result  of infection with  this  group.  Experimental  studies 
with psittacosis vaccines have often been disappointing and have at best shown 
partial protection.  Studies in the past have failed to reveal clear-cut evidence 
of antibody response in trachoma infection. Trachoma is a superficial disease of 
the conjunctival cells of the eye and the role of humoral antibodies both in the 
natural  disease  and  in preventing  infection  are  not known.  Although  recent 
studies  have  suggested  that  complement-fixing antibodies  develop  in  tracho- 
matous patients  (9),  these results have not been confirmed. 
The  results  of  the  studies  recorded  in  this  paper  provide  evidence  that 
humoral  antibodies  develop  during  the  course of experimental  trachoma  eye 
infections  and  that  vaccine  made from trachoma  virus  favorably affects  the 
course of these infections. 
Materials and Methods 
ttuman  Volunteers.--Seven  volunteers were recruited  from the Provincial Taipei  School 
for Blind and Mute,  Taipei,  Taiwan.  They were selected from the student  volunteers  ex- 
amined at the school who showed no evidence of previous trachoma infection. All had normal 
conjunctivas  before inoculation. Volunteer  1 was the only one with a normal cornea. The 
age, sex, and clinical eye diagnoses were as follows: 
Volunteer  Clinical Description before Experiment 
1. Male, 11 yrs.  Congenital  cataract with convergent  concomitant  strabismus, 
vision (from  llth  International Test Table): 1 m/O.1 non- 
corrigunt (n.c.) for both eyes. Cornea of both eyes was normal. J.  T.  GRAYSTON, S.  WANG,  Y.  YANG,  AND  R.  L.  WOOLRIDGE  1011 
2.  Male, 12 yrs. 
3.  Male, 17 yrs. 
4.  Male, 24 yrs. 
5.  Male, 22 yrs. 
6.  Female, 18 yrs. 
7.  Female, 25 yrs. 
Bulbar phthisis with band shape degeneration of cornea, blind 
in both eyes. 
Total  staphyloma  with  band  shape  degeneration of  cornea, 
blind in right (R) eye. 
Adherent  corneal  leukoma  with  artificial  iris  defect,  vision: 
1 m/0.1 n.c. in left (L) eye. 
Bulbar phthisis,  blind  in  R  eye. 
Adherent corneal leukoma with artificial iris coloboma, vision: 
numerous digitorum (n.d.)/20 cm n.c. in L eye. 
Congenital cataract  with  horizontal and  rotating  nystagmus, 
vision: 0.1 in R  eye. 
Pupillar ectopia with aphakia and neuroretinochoroidal atrophy, 
blind in L eye. 
Bilateral total corneal staphyloma, blind in both eyes. 
Juvenile glaucoma and optic nerve atrophy of both eyes. Intra- 
ocular pressure and vision: 22  mm Hg;  3  m/0.1  n.c.  for R 
eye, and 41 mm Hg; n.d./25 cm for L eye. 
These volunteers were admitted to the NAMRU-2 ward on July 15, 1959, at the beg6nning 
of  the school summer vacation.  They were  hospitalized for a  period of 9  months, except 
volunteer 7 who was discharged at the end of the first 4 weeks. When the school term began 
in late September, the voinnteers were allowed to attend classes, but they returned to the 
ward for meals and overnight. After 9 months, when the first period of treatment with oxy- 
tetracycline eye ointment was finished, they were discharged from the ward. Close observation 
was continued by periodic examination. 
The clinical illnesses were more acute than would be expected in natural trachoma. Despite 
the acute nature of the disease, the volunteers remained comfortable throughout the experi- 
ment. The lack of discomfort was undoubtedly related to their blindness. 
Virus  Inoculums.  Tradwma:  The  first  Talwan  virus  isolate,  TRICA  Talwan-l-1958, 
abbreviated TW-I  (formeriy called  TW-10)  (10)  was  used.  Yolk  sacs of the seventh egg 
passage virus were pooled and a  20 per cent yolk sac suspension made in 10 per cent broth 
saline.  After removing gross debris by light centrifugation,  the supematant fluid  was  dis- 
tributed in 1 ml quantities to a number of screw-capped vials and stored frozen in an electric 
freezer at --65°C. The inocuium in this experiment had been stored 4 months. Titration in the 
yolk sac of eggs of the material used on the day of the first inoculations was ELDs0:10  -l's 
and EIDs0:10  ~'6. The inocuhims used were diluted with a 20 per cent normal yolk sac sus- 
pension. 
Adenovirus Type 4:  The prototype adenovirus type 4 harvested from HeLa cell cultures 
at their complete cytopathogeuic stage was used.  A  1:2 dilution was made in 20 per cent 
normal yolk sac suspension. 
Control: A 20 per cent normal yolk sac suspension derived from 12-day-old embryonated 
eggs was prepared like the trachoma virus inoculum for a control. 
Inoculation.--Each  of the inoculums had a  similar appearance in the gross.  They were 
prepared in sterile coded test tubes in 1 ml amounts for each volunteer. The volunteers were 
placed on their backs and the upper lid of one eye everted exposing the upper fornix. The 
conjunctiva of the upper foruix and the palpebral region was gently but firmly rubbed with a 
sterile cotton swab soaked in the inoculum. An additional drop of the inoculum was placed 
on the conjunctiva and the lid reverted. The eye was then bandaged with sterile gauze. The 
1 The designation T1LIC  for the trachoma-inclusion conjunctivitis virus group has been 
suggested by Dr. James Gear. 1012  TRACHOMA INFECTION 
ophthalmologist (YFY) who carried out the inoculation procedure was not informed of the 
materials used for inoeulum. 
Clinical Observations of the Volunteers.--The  eyes of each volunteer were examined by the 
ophthalmologist at 1 to 3 day intervals during the first 2 months of the experiment. Observa- 
tions were made at weekly intervals through 8 months and then less frequently up to 1 year. 
At  each examination,  findings were  recorded  by  severity  (A-  to  +q-A-)  and  appropriate 
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+  Inclusion  bodies found  0  I.B.  not found  V  Trachoma  virus isolated  --  T.V.  not isolated 
Ad-4  Adenovirus  type4 isolated 
CHART 1. The horizontal bars in all of the charts indicate follicular conjunctivitis, and their 
height  its  severity. Findings for 1 month after experimental eye inoculation of seven blind 
human volunteers with trachoma virus, adenovirus, and normal yolk sac. 
anatomic location for discharge, congestion, swelling, turbidity, pseudomembrane, petechial 
hemorrhage, hypertrophy, follicle,  papilla, pannus, scar, and lymphadenopathy. Magnifying 
lenses of 13 and 20 diopters and a slit lamp were used for the clinical examinations. 
Laboratory Examinaticn.--Laboratory  examinations  consisted  of  bacteriologic  culture, 
examination of conjunctival smears for inclusion bodies, embryonated egg yolk sac culture 
for trachoma virus, and trachoma complement fixation serology. The results were not given 
to the ophthalmologist to avoid any influence on his clinical observations. The methods used 
were as follows. 
Bacteriology: A sterile platinum loop was rubbed against the lower fornix of each eye using 
great care to avoid lid or hairs. The loop was immediately streaked on sheep blood agar plates. 
Bacterial colonies appearing on the plates after 48 hours' incubation at 37°C were identified 
by appropriate techniques. 
Inclusion bodies: Serapings from the conjunctiva of the upper lid were taken with a sterile j.  T.  GRAYSTON, S.  WANG,  Y.  YANG,  AND  R.  L.  WOOLRIDGE  1013 
platinum spatula and streaked on a clean slide.  This was quickly dried in air and fixed with 
anhydrous  methylalcohol for  5  minutes  and  again  air-dried.  The slides were stained  with 
Giemsa solution type B class 2 obtained from Hartman Leddon Co., Philadelphia. The detailed 
instructions on use of the stain which accompanied the product were followed.  Each slide was 
examined microscopically for 30 minutes and  the following gradings for the presence of in- 
clusion bodies recorded: 0, No typical inclusion bodies found;  +, Typical inclusions found 
only in 1 or 2 places on the slide; ++,  Typical inclusions found in several areas of the slide or 
2 to 3 inclusions in a single field; +++,  Typical inclusions easily found in many areas of the 
slide or 3 to 5 inclusions in a single field. 
Virus Isolation.--Our method  for isolation of trachoma  virus has  been  published  (10). 
When swabbing the conjunctiva great care was exercised to avoid touching other areas and 
contaminating the specimen. Two egg passages were carried out for each eye specimen before 
declaring it negative. The isolation of adenovirus was accomplished in HeLa cell tissue culture. 
Serology.--Trachoma antibody was measured by a complement fixation (CF) test using a 
purified elementary body antigen which has been shown to give a specific reaction for trachoma 
(11).  Neutralizing antibody  against  adenovirus  type  4  was  measured  in  HeLa cells  (12). 
Results of both tests are presented as reciprocals of original serum dilutions. 
Trachoma Vaccine.--The vaccine used was prepared from both TW-1 and TRIC-Taiwan- 
3-1959  (formerly TW-29)  strains  of trachoma  virus.  The  method of preparation  has been 
presented  in  a  previous report  (8).  Partially  purified  elementary  bodies  inactivated  with 
formalin and attached  to aluminum hydroxide particles were used as vaccine. This vaccine 
contained a 20 per cent concentration of original yolk sac by weight and was similar to that 
used in an antibody response study in humans (8, 13) and half the concentration employed in 
field trials (14). The placebo was prepared from normal yolk sacs in a similar fashion. 
Treatmem.---Oxytetracycline ophthalmic  ointment  with  polymyxin  B  sulfate  (Pfizer 
Laboratories,  Brooklyn,  New York)  was used  for local application  and  sulfamethoxypyri- 
dazine (MIDICEL: Parke Davis & Co., Detroit) was used for oral therapy. 
RESULTS 
Differentiation Between Inoculums 
Seven blind eyes, one from each of the seven volunteers, were subjected to the 
first inoculation on July 17,  1959.  The results following inoculation during the 
first 4  weeks are presented  in Chart  1. 
The two eyes which received normal yolk sac did not show an inflammatory process 
except for slight congestion and swelling of the conjunctiva, probably due to manipu- 
lation. The four eyes inoculated with TW-1  and  the one inoculated with adenovirus 
type 4 showed acute follicular conjunctivitis within a week. The inflammatory process 
was  milder and  of shorter  duration  in volunteer 6  who received adenovirus  type 4. 
In the adenovirus infection there was not as much congestion or edema, fewer follicles 
appeared  and they were more transparent.  After 2 weeks the follicular conjunctivitis 
began  to  decrease  and  by  1 month  after inoculation,  the eye appeared  normal.  In- 
fection with adenovirus type 4  was substantiated  by the reisolation of the virus and 
by an  increase of neutralizing antibody  titer.  The adenovirus  type 4  antibody  titer 
on 0, 12, 38, and 52 days after inoculation was  <4, 4, 4, and 8. In the volunteers who 
received TW-1  virus, irrespective of dilution, the signs showed progression over the 
4 week period. 1014  TRACHOMA  INFECTION 
The  second inoculation was  carried out  in  three volunteers  on  August  15, 
1959, with greater dilutions of the TW-1 virus pool which had been used in the 
first inoculation. 
One eye (No. 5-L) which had been inoculated with normal yolk sac before and two 
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C~AI~T 2. Findings for 1 year after experimental trachoma eye infection of a blind human 
volunteer with normal corneas. 
of virus. The results of the second inoculation are shown at the bottom of Chart 1. 
All three eyes developed follicular conjunctivitis. The 10  -4 dilution of the virus, which 
represented the limit of dilution of yolk sac infectivity (EIDs0:10  -3"6) caused infec- 
tion in the eye inoculated, with an acute onset similar to that seen in the eyes inocu- 
lated with more concentrated virus. 
Typical inclusion bodies of Halberstaedter-Prowazek were demonstrated in 
each eye inoculated with TW-1, starting 5 to 6 days after inoculation. Trachoma 
virus was also isolated from each of these eyes on one or more occasions during 
the first 4 weeks. J. T. GRAYSTON,  S. WANG,  Y. YANG,  AND  R. L. WOOLRIDGE  I015 
Clinical Findings in Experimental Trachoma 
The clinical illnesses in the six volunteers who received TW-1 virus inocula- 
tion were observed for a  year. 
A  serosuppurative discharge was found in each inoculated eye the 2nd day after 
inoculation and  persisted for  3  to 8  months.  The  conjunctivas became  congested, 
turbid, and edematous in a few days. Follicles  developed by 6 days, first in the fornices 
and then in the palpebral conjunctivas of both upper and lower lids. Petechial hemor- 
rhages  of  the  conjunctivas  and  pseudomembranes were  also present.  Preauricular 
lymph nodes were tender in all cases. The  follicular conjunctivitis increased in in- 
tensity and progressed in severity for 3 to 4 months. Follicles  in the bulbar conjunctiva 
was found in each case 4 to 5 months after infection. Decrease in acute changes there- 
after was accompanied by appearance of chronic changes.  Trachomatous scars de- 
veloped in the infected eyes of each volunteer 5 to 10 months after inoculation. 
Figs. 1 to 6 show different stages of the clinical course including the acute on- 
set and the development of pannus and scar. Figs. 7 and 8 show typical inclu- 
sion bodies. 
A sample of the clinical course is illustrated in Chart 2 where clinical changes 
and some laboratory findings for volunteer 1 are presented. 
The approximate grades of each main finding are graphically expressed in the chart" 
Since No.  1 was  the only volunteer with  undamaged  corneas,  the development of 
pannus was carefully observed. Initial pannus was first found by slit lamp during the 
4th week after inoculation. Pannus formation progressed for 3 months with the maxi- 
mum extent of vascularization being 1 mm from the limbus. The pannus remained 
stationary until treatment was completed. Epithelial keratitis was seen during the 
formation of pannus but disappeared during the 4th month.  Papillary hypertrophy 
was found after development of follicles and also persisted until completion of treat- 
ment. The acute symptoms in the left eye continued for 4 months and then gradually 
decreased. The  follicles became  gelatinous after  5  months  and  conjunctival scars, 
typical of trachoma, developed during the 8th month. 
The right eye of volunteer 1 remained normal for 41/~ months, but then a trachoma- 
tous  follicular conjunctivitis  developed.  Preauricular  lymphadenopathy,  papillary 
hypertrophy, pannus,  and  later scar formation were  observed. The  right eye was 
treated with oxytetracycline eye ointment during the 8th and 9th months and  the 
left eye during the 9th month. Local treatment of both eyes was discontinued at the 
end of the 9th month. Both eyes had an acute reactivation of disease by the end of 
the 10th month. A course of sulfamethoxypyridazine for 1 month cleared up the re- 
current disease. There remained some flat and transparent follicles and linear scars 
in the conjunctiva on the left and fine papillae and scars on the right at the end of 
1 year's observation. 
The Effect of Trachoma Vaccine 
Toward the end of the 2nd month of the experiment when the trachomatous 
changes had become well developed in each inoculated eye, the volunteers were 1016  TRACHOMA  INFECTION 
divided into two groups in order to study the effect of vaccine on the course of 
their illness. Three of the volunteers (Nos. 2, 4, 5) were given a series of inocu- 
lations  with  trachoma  vaccine  while  the  other  three  (Nos.  1,  3,  6)  received 
placebo injections.  Again the identity of the volunteers receiving vaccine was 
withheld from the  ophthalmologist  making  the  clinical  evaluation.  A  total  of 
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CHART 3.  The results of egg yolk sac cultures for virus and  conjunctival ceil smears for 
inclusion bodies in  six blind human  volunteers infected with  trachoma  virus.  The  dotted 
areas show the periods of antibiotic and sulfa drug treatment. 
six 2 ml intramuscular injections were given. Except for local pain and a  24 hr 
temperature  rise  experienced  by some volunteers following the  alum vaccine, 
there were no reactions. 
In Chart 3, findings in the six volunteers are shown over the 1 year course of the 
experiment. Natural spread of infection to the uninoculated eye occurred in three of 
the volunteers.  First,  No.  6 to the left eye within  1 month after inoculation,  then 
No. 1 to the right eye at 4~  months, and No. 3 to the left eye after 5 to 6 months. 
These volunteers all received the placebo. There was no spread of infection in volun- 
teers 4 and 5 of the vaccine group. Volunteer 2 had been inoculated in both eyes. J.  T.  GRAYSTON,  S.  WANG~ Y.  YAN%  AND  R.  L.  WOOLRIDGE  1017 
Local treatment with oxytetracycline ointment (four times daily) was applied to 
the eyes of No. 1-R and No. 3-L (spread infections) during the 8th month; then both 
eyes of the six volunteers were treated during the 9th month. All trachomatous changes 
showed great improvement and local treatment was discontinued at the end of the 
9th month. The volunteers were discharged from the ward at this time. 
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CHART 4. Complement  fixation antibodies with trachoma virus antigen during the course 
of experimental trachoma infections in six human volunteers.  The numbers  are complement 
fixation antibody titers (reciprocals of original serum dilutions). 
By the end of the 10th month when the volunteers were called back for examina- 
tion, reactivation of illness was found in both eyes of volunteers 1, 3, and 6. These 
were the volunteers who had been given the placebo. There was no reactivation of 
illness in the three volunteers who had received vaccine. 
A  course of oral  administration of sulfamethoxypyridazine was  commenced im- 
mediately in all volunteers. Each was given 1 gm of the drug on the 1st day, followed 
by a  daily dose (6 days per week) of 0.25  to 0.5 gm (depending on body size) for a 
month. The reactivated disease improved rapidly during the course of this sulfa drug 
administration, following which all cases appeared cured.  Residual clinical findings 
included eonjunctival scars and  a  few flat transparent follicles and/or fine papillae. 1018  TRACHOMA IN]~ECTION 
The laboratory findings and dinical picture in volunteers 4 and 5 improved some- 
what faster than in the others during the 4th to 9th month. The impression of more 
rapid healing in these volunteers who received vaccine was supported by the lack of 
spread  infection and by their  more favorable response  to eye ointment treatment. 
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CrrA~T 5.  Results  of bacteriologic cultures  of conjunctiva  during  the course of experi- 
mental trachoma infections in six human volunteers. 
Laboratory Findings 
A  summary  of the  results  of examinations  for inclusion  bodies  and  of at- 
tempts  at  reisolation  of  trachoma  virus  are  also  presented  in  Chart  3.  The 
typical inclusion bodies of Halberstaedter-Prowazek  (also substantiated by the 
demonstration  of positive  glycogen reaction  of  the  matrix  with  iodine  stain) 
were found in the epithelial cells of the conjunctiva of all infected eyes.  There 
was some correlation between numbers of inclusion bodies  and clinical activity 
of the disease. Typical inclusion bodies were also found in the corneal scrapings 
of the right eye of volunteer 3 on several occasions (see Fig.  7). j. w. CRAYSTON,  S. WANG,  Y. YANO, AND R. L. WOOLRn)OE  1019 
Virus isolations  were  obtained on numerous occasions  from each inoculated eye 
with the exception of volunteer 5 from which there was only one isolation at the be- 
ginning of infection. Several early eye swab specimens were contaminated. In volunteer 
5, inclusion  bodies were found up to the beginning  of the 7th month. In the other 
volunteers, virus isolations  and/or inclusions were obtained up to the time oxytetra- 
cydine ointment treatment was begun. The spread infections  and  the reactivation 
diseases after oxytetracydine ointment were also substantiated by demonstration of 
inclusions  and/or virus isolations.  There were no positive laboratory findings  after 
sulfa drug treatment. 
Results of CF tests for trachoma, performed with serums obtained through- 
out the course of the experiment, are presented in Chart 4. 
The  three  volunteers  (Nos.  2,  4,  5)  receiving vaccine showed  higher  and  more 
persistent titers than those receiving placebo. Serum antibody titers due to infection 
alone fluctuated between 8 and 16 with one 32 in the three volunteers (Nos.  1, 3, 6) 
not receiving  vaccine.  The pattern of antibody titer increase  and decline during the 
course of infection varied among the volunteers, but there was a definite tendency for 
the antibody titers  to fall while  active disease  was still  present. 
The results of bacteriologic cultures of the six volunteers during the experi- 
ment are given in Chart 5. Generally, the conjunctivas were free from bacteria. 
Staphylococcus pyogenes was  the  only pathogenic  bacteria  found  during  the 
experiment. There was no correlation between isolated bacteria and the disease 
in the eyes, nor were there any particular organisms associated with severity of 
illness. 
DISCUSSION 
These six human  volunteer  infections,  in  addition  to providing important 
evidence that the large virus agents isolated from trachomatous eyes are the 
etiologic agent of trachoma, have shown that vaccine prepared from egg yolk 
sac-grown  virus  exerts  a  favorable influence  on  the  course  of  experimental 
trachoma infections. These findings are encouraging to an effort to develop a 
practical  and  effective preventive vaccine.  We have  employed experimental 
trachoma vaccines in humans, both in antibody response studies and in small 
scale field protection studies. The preliminary results of these studies have been 
encouraging (14, 15). Snyder et al (16) have reported an experiment in which one 
person given vaccine had a milder experimental trachoma infection than a con- 
trol not given vaccine. 
Monkeys  and  other  primates  are  the  only  laboratory  animals  in  which 
trachomatous  eye disease can be reproduced.  As experience has been gained 
with monkey eye infections, disease more like that observed in humans has been 
obtained including the production of pannus  (17). However, only some of the 
trachoma virus isolates have proven pathogenic for the monkey eye and only 
one strain has produced acute disease in high dilution (17,  18).  Using monkeys 1020  TRACHOMA  INFECTION 
for studies of vaccine protection, we have obtained evidence that under certain 
circumstances, vaccines may prevent or modify experimental disease  (8,  14). 
Collier (19) has obtained protection from infections with the closely related in- 
clusion blennorrhea virus in baboons with homologous vaccine, and Dawson et al. 
(20)  have modified monkey trachoma infection with vaccine. 
The demonstration of a favorable effect of trachoma vaccine on the course 
of experimental infection suggests that humoral antibodies can play a role in 
trachoma  and  serves  to disprove partially  theoretical objections  to  vaccine. 
Many problems remain in the development of an effective trachoma vaccine. 
The use of infected yolk sacs  to produce vaccine poses difficult problems of 
purification. However, we have so far been unable to adapt any of our trachoma 
virus strains either to other chambers of the egg or to tissue culture. An addi- 
tional problem concerns the number of different antigenic strains of trachoma 
virus. Studies with the mouse toxin prevention test have suggested that there 
are at least two separate trachoma strains  (21)  and there may be more (22). 
The significance of the strain differences in the mouse protection test in rela- 
tionship to human protection against trachoma remains to be determined. The 
possibility  of  significant  strain  differences  complicates  the  development  of 
vaccine. 
SUMMARY 
The TRIC-Taiwan-1-1958  strain  of elementary body virus isolated  from a 
trachoma patient  on Taiwan has been proven capable of  reproducing trachoma 
by experimental inoculation  of six human volunteers.  Virus material derived 
from the seventh passage in embryonated hen eggs  caused the clinical  picture 
of trachoma in every inoculation,  even at the dilution  of 10  -4 of infccted  yolk 
sacs (approximately I EIDs0). There was a similar  clinical  picture with each 
inoculation  beginning with an acute follicular  conjunctivitis  which progressed 
for 4 months and then persisted  with chronic  changes until 9 months when 
treatment was begun. The illness  was generally  morc acute than would be ex- 
pected in natural trachoma. That trachoma was reproduced was shown by the 
involvement of the cornea with epithelial  keratitis  and pannus, and by the 
occurrence of gelatinous  follicles  and cvcntual cicatrization  of the conjunctiva. 
These clinical  findings  were supported by repcatcd demonstrations of typical 
inclusion  bodies  of  Halberstacdter-Prowazek from conjunctival  and even  corneal 
cclls,  by repeated reisolation  of elementary body virus  in egg yolk sacs,  and by 
the development of complement-fixing antibody with a "specific"  trachoma 
antigen in each volunteer. Control inoculations  with adenovirus type 4 and 
normal yolk sac showed different  clinical  and laboratory findings. 
Experimental trachoma vaccine was given to three  of the  voluntecrs  to study 
its  effect  on the course  of  illness.  An antibody response to the  vaccine was dem- 
onstrated and there was a modification  of disease  in the volunteers receiving 
vaccine.  While the three  volunteers  who received  placebo each developed cross- J. T. GRAYSTON,  S. WANG,  Y. YANG,  AND  R. L. WOOLRIDGE  1021 
infection of their uninoculated eye and had an acute reactivation of the bilateral 
disease after 1 to 2 months of antibiotic eye ointment therapy, the vaccinated 
volunteers  remained  free  of  infection in  uninoculated  eyes  and  showed  no 
relapse after ointment therapy. 
Treatment with sulfamethoxypyridazine, a sulfa drug with prolonged action, 
proved to be an effective and relatively simple method of therapy for experi- 
mental trachoma. 
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EXPLANATION  OF PLATES 
PLATE 114 
FIC. 1.  Volunteer 5 (left eye). Normal conjunctiva 15 days after inoculation  with 
normal yolk sac.  X 4. 
FIG. 2.  Volunteer 5 (left eye). Acute follicular conjunctivitis 18 days after inocula- 
tion of TW-1. The conjunctiva is congested,  swollen, and turbid. A number of large 
follicles are present and residual  patches of pseudomembrane (arrows)  can be seen. 
X4. 
FIG. 3.  Volunteer 3  (right eye).  Conjunctiva 35  days after inoculation  of TW-1 
shows distortion of vessel pattern by edema and follicular and papillary hypertrophy 
(arrow).  X 4. 
FIG. 4.  Volunteer 1 (left eye). Enlargement of upper cornea 54 days after infection 
with TW-1 showing pannus formation with vessel infiltration of about 1 mm (arrow). 
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FIc. 5.  Volunteer 2 (left eye). Conjunctiva 240 days after inoculation with TW-1. 
"Cobble-stone" appearance due  to  numerous large gelatinous follicles  which  have 
coalesced to form folds on the fornix conjunctiva. ×  4. 
FIO. 6.  Volunteer 2  (left eye).  Conjunctiva 344  days after  infection with TW-1 
and 2 weeks after sulfa drug treatment. The inflammatory  process has subsided leaving 
some papillae, transparent follicles, and scars  (arrow)  on the upper fornix.  X  4. 
FIC. 7.  Giemsa-stained smear of corneal scraping from volunteer 3,  196 days after 
infection showing a  corneal cell with an inclusion body in an intermediate stage of 
development X 950. 
Fro. 8.  Giemsa-stained conjunctival cell smear of left eye of volunteer 2, 186 days 
after infection showing inclusion bodies in the late vesicle stage prior to rupture and 
release of elementary bodies X 950. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 115  PLATE  115 
(Grayston et al.: Trachoma infection) 